Topics

Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

04:21 EDT 1 May 2019 | Pharmaceutical Business Review

This medicine is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors. The agreement

The post Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors appeared first on Pharmaceutical Business review.

Original Article: Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

NEXT ARTICLE

More From BioPortfolio on "Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...